Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6656042 | 0.72 | MAPT (0.42) | MAPTHPGDKMT2ANPSR1TDP1 | |
| SCHEMBL7695936 | 0.68 | MAPT (0.36) | MAPTHPGDKMT2ANPSR1TDP1 | |
| SCHEMBL6603479 | 0.68 | CALM1 (0.38) | ALDH1A1 | |
| SCHEMBL14889308 | 0.63 | ALDH1A1 (0.44) | MAPTHPGDKMT2ATDP1ALDH1A1 | |
| Biphenyl SCHEMBL15610250 | 0.61 | ALDH1A1 (0.69) | MAPTTDP1ALDH1A1NPC1MAPK1 | |
| SCHEMBL576916 | 0.60 | ALDH1A1 (0.47) | MAPTHPGDKMT2ATDP1ALDH1A1 | |
| SCHEMBL2282129 | 0.58 | NISCH (0.44) | KMT2AALDH1A1NPC1MAPK1RAB9A | |
| Biphenyl SCHEMBL15610556 | 0.57 | ALDH1A1 (0.60) | MAPTKMT2ATDP1ALDH1A1NPC1 | |
| Biphenyl SCHEMBL278264 | 0.57 | ALDH1A1 (0.60) | MAPTTDP1ALDH1A1NPC1MAPK1 | |
| SCHEMBL12997586 | 0.55 | ALDH1A1 (0.47) | MAPTKMT2ATDP1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0931072-A1 | 1-SULFONYL-3-PHENYLPYRAZOLES AND THEIR USE AS HERBICIDES AND FOR DESICCATING OR DEFOLIATING PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-28 | — | — | EP | claimed |
| WO-1998012182-A1 | 1-SULFONYL-3-PHENYLPYRAZOLES AND THEIR USE AS HERBICIDES AND FOR DESICCATING OR DEFOLIATING PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-26 | — | — | WO | claimed |
| EP-3585791-B1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-10-16 | — | — | EP | disclosed |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-12-07 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| CN-110536892-B | Novel bicyclic pyrazole derivatives | 拜耳动物保健有限责任公司 | 2023-05-12 | — | — | CN | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| US-11130768-B2 | Bicyclic pyrazole derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| US-20200190111-A1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
| US-6472416-B1 | Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors | ABBOTT LABORATORIES | 2002-10-29 | — | — | US | disclosed |
| US-6472416-B1 | Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors | ABBOTT LABORATORIES | 2002-10-29 | — | — | US | disclosed |
| US-6472416-B1 | Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors | ABBOTT LABORATORIES | 2002-10-29 | — | — | US | disclosed |
| EP-1206474-A1 | SULFONYLPHENYLPYRAZOLE COMPOUNDS USEFUL AS COX-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1206474-A1 | SULFONYLPHENYLPYRAZOLE COMPOUNDS USEFUL AS COX-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001016138-A1 | SULFONYLPHENYLPYRAZOLE COMPOUNDS USEFUL AS COX-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2001016138-A1 | SULFONYLPHENYLPYRAZOLE COMPOUNDS USEFUL AS COX-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0931072-A1 | 1-SULFONYL-3-PHENYLPYRAZOLES AND THEIR USE AS HERBICIDES AND FOR DESICCATING OR DEFOLIATING PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998012182-A1 | 1-SULFONYL-3-PHENYLPYRAZOLES AND THEIR USE AS HERBICIDES AND FOR DESICCATING OR DEFOLIATING PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | MAPT 4171/4885HPGD 1491/4885KMT2A 1488/4885 |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | MAPT 4103/4885HPGD 1504/4885KMT2A 1719/4885 |
| US-20200190111-A1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | CYP1B1, QPCT, CYP4B1 | MAPT 4074/4885HPGD 377/4885KMT2A 2707/4885 |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | MAPT 4828/4885HPGD 54/4885KMT2A 3963/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | MAPT 4828/4885HPGD 54/4885KMT2A 3963/4885 |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | MAPT 4838/4885HPGD 48/4885KMT2A 3275/4885 |
| US-11130768-B2 | Bicyclic pyrazole derivatives | CYP1B1, CYP3A43, CYP3A5 | MAPT 4008/4885HPGD 408/4885KMT2A 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.